124 related articles for article (PubMed ID: 35073411)
1. A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins.
Metin Z; Celepli P
Int J Dermatol; 2022 May; 61(5):639-641. PubMed ID: 35073411
[No Abstract] [Full Text] [Related]
2. Morphea and COVID-19 mRNA vaccine.
Sookaromdee P; Wiwanitkit V
Int J Dermatol; 2022 May; 61(5):e162. PubMed ID: 35230704
[No Abstract] [Full Text] [Related]
3. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.
Trougakos IP; Terpos E; Alexopoulos H; Politou M; Paraskevis D; Scorilas A; Kastritis E; Andreakos E; Dimopoulos MA
Trends Mol Med; 2022 Jul; 28(7):542-554. PubMed ID: 35537987
[TBL] [Abstract][Full Text] [Related]
4. Response to 'Unlikely influence of ABO blood group polymorphism on antibody response to COVID-19 mRNA vaccine against SARS-CoV-2 spike protein'.
Bordino V; Vicentini C; Zotti CM
Vox Sang; 2022 Sep; 117(9):1128. PubMed ID: 35919936
[No Abstract] [Full Text] [Related]
5. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
Pascolo S
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
[TBL] [Abstract][Full Text] [Related]
7. "Polymutant" Spike Points Way Toward More Durable COVID-19 Vaccine.
Abbasi J
JAMA; 2021 Nov; 326(18):1784. PubMed ID: 34751729
[No Abstract] [Full Text] [Related]
8. Humoral response against spike protein and fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects: What should be for the seventh dose?
Wiwanitkit S; Wiwanitkit V
Hum Vaccin Immunother; 2023 Dec; 19(3):2295074. PubMed ID: 38111337
[No Abstract] [Full Text] [Related]
9. Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist.
Pulsipher KJ; Presley CL; Waller JD; Szeto MD; Laughter MR; Dellavalle RP
J Drugs Dermatol; 2021 Mar; 20(3):351-352. PubMed ID: 33683080
[No Abstract] [Full Text] [Related]
10. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
11. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
[TBL] [Abstract][Full Text] [Related]
13. Audio Interview: Can We Make More Effective Covid-19 Vaccines?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2022 Mar; 386(11):e36. PubMed ID: 35294821
[No Abstract] [Full Text] [Related]
14. Recombinant vaccines for COVID-19.
Yadav T; Srivastava N; Mishra G; Dhama K; Kumar S; Puri B; Saxena SK
Hum Vaccin Immunother; 2020 Dec; 16(12):2905-2912. PubMed ID: 33232211
[TBL] [Abstract][Full Text] [Related]
15. Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review.
Antoñanzas J; Rodríguez-Garijo N; Estenaga Á; Morelló-Vicente A; España A; Aguado L
Dermatol Ther; 2022 Sep; 35(9):e15709. PubMed ID: 35811413
[TBL] [Abstract][Full Text] [Related]
16. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
17. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
[TBL] [Abstract][Full Text] [Related]
19. The spike hypothesis in vaccine-induced adverse effects: questions and answers.
Cosentino M; Marino F
Trends Mol Med; 2022 Oct; 28(10):797-799. PubMed ID: 36114089
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
Boyarsky BJ; Werbel WA; Avery RK; Tobian AAR; Massie AB; Segev DL; Garonzik-Wang JM
JAMA; 2021 May; 325(17):1784-1786. PubMed ID: 33720292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
